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Purpose: Activation of polyol pathway due to increased aldose reductase (ALR2) activity has been implicated in the
development of diabetic complications including diabetic retinopathy (DR), a leading cause of blindness. However, the
relationship  between  hyperglycemia-induced  activation  of  polyol  pathway  in  retina  and  DR  is  still  uncertain.  We
investigated the relationship between ALR2 levels and human DR by measuring ALR2 activity and its product, sorbitol,
in erythrocytes.
Methods: We enrolled 362 type 2 diabetic subjects (T2D) with and without DR and 66 normal subjects in this clinical
case-control study. Clinical evaluation of DR in T2D patients was done by fundus examination. ALR2 activity and sorbitol
levels along with glucose and glycosylated hemoglobin (HbA1C) levels in erythrocytes were determined.
Results: T2D patients with DR showed significantly higher specific activity of ALR2 as compared to T2D patients without
DR. Elevated levels of sorbitol in T2D patients with DR, as compared to T2D patients without DR, corroborated the
increased ALR2 activity in erythrocytes of DR patients. However, the increased ALR2 activity was not significantly
associated with diabetes duration, age, and HbA1C in both the DR group and total T2D subjects.
Conclusions: Levels of ALR2 activity as well as sorbitol in erythrocytes may have value as a quantitative trait to be
included among other markers to establish a risk profile for development of DR.
About 200 million people across the globe are estimated
to have diabetes of which Southeast Asia alone is home to 46.9
million diabetics and India has 41 million diabetics [1,2]. Type
2  diabetes  (T2D)  accounts  for  roughly  90  percent  of  all
diagnosed cases of diabetes [2]. The prevalence of diabetes in
India is estimated to be between 5.9%–24.2% (average of
12.1%) [3,4]. It is higher in developed countries compared to
developing  countries.  While  in  developing  countries  the
average age of people with diabetes is between 45 and 64 years
of age, in developed nations it is 65 years and older. These
statistics indicate that the world, particularly India, is facing
a  growing  diabetes  epidemic  of  potentially  devastating
proportions. Prolonged exposure to chronic hyperglycemia,
without proper management, can lead to various short-term
and long-term secondary complications, both of macro and
microvascular  nature,  which  represent  the  main  cause  of
morbidity  and  mortality  in  diabetic  patients  [5].
Hyperglycemia is the major determinant of microvascular
complications in diabetes [6,7].
Diabetic retinopathy (DR), a vascular disorder affecting
the microvasculature of the retina, is a leading cause of adult
blindness and is the most common complication of diabetes
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[8]. It is estimated that DR develops in more than 75% of
diabetics  who  have  had  diabetes  for  15–20  years.  It  is
projected that by 2005, diabetes will affect 300 million people
worldwide, of whom 10% will develop visual impairment
secondary to DR [9]. While a study reported the prevalence
of DR among diabetic subjects (both rural and urban) in India
was 10% [10], another study reported the prevalence of DR
about 17% among urban diabetic subjects in India [11]. In a
clinical study the prevalence of DR was 34% among T2D
patients [12]. The prevalence of DR was 0.5% in the general
rural populations of Southern India (this in total population
but not among diabetics) and 10.5% among diabetic patients
[13].
Although  the  exact  mechanism  involved  in  the
pathogenesis  is  not  known,  many  biochemical  pathways
associated with hyperglycemia have been implicated in the
development of diabetic complications including DR. These
include  glucose  autoxidation,  polyol  pathway,  prostanoid
synthesis, protein glycation, protein kinase C activation, and
the  hexosamine  pathway  [5].  Among  these,  the  polyol
pathway  has  been  extensively  studied.  Aldose  reductase
(ALR2; EC: 1.1.1.21), the first and rate-limiting enzyme in
the  polyol  pathway,  reduces  glucose  to  sorbitol  using
nicotinamide adenine dinucleotide phosphate (NADPH) as a
cofactor. Sorbitol is then metabolized to fructose by sorbitol
dehydrogenase [14]. Studies on animal models of diabetes and
galactosemia suggest increased polyol pathway activity in the
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593pathogenesis of DR [15]. Further, several studies based on
specific inhibitors of ALR2 support the role of polyol pathway
in the pathology of DR [16-18]. Retinal capillary pericytes
contain ALR2, and the accumulation of polyols in pericytes
has  been  linked  to  their  degeneration  and  selective  death
[19]. Pericyte loss, the major event of early DR, has been
observed in galactose-fed dogs that developed retinopathy
[20]. In addition, the involvement of ALR2 in DR has been
recently  supported  by  the  findings  that  ALR2  inhibitor
prevented  a  spectrum  of  neural,  glial,  and  vascular
abnormalities associated with development of DR in rat and
humans [17,18]. Furthermore, evidence for the involvement
of  ALR2  as  a  risk  factor  for  DR  and  other  diabetic
complications  comes  from  genetic  polymorphism  studies
[21,22]. Several studies indicate that the Z-2 allele and a
putative  protective  allele,  Z+2,  of  ALR2  are  significantly
associated with DR [21-24]. Although, most animal studies
with ALR2 inhibitors (ARI) have yielded encouraging results
(considering some inconsistent data), on the whole, clinical
trials of ARI have failed to shown efficacy against various
diabetic  complications.  This  may  be  due,  in  part,  to
differences in tissue levels of ALR2 in rodents as compared
with  humans.  In  addition,  development  of  diabetic
complications in humans may be influenced by metabolic and
signaling pathways that have a less significant impact on the
pathogenesis of complications in animal models. In principle,
all diabetic patients might be expected to develop diabetic
microvascular complications if hyperglycemia alone were the
triggering factor for activation of the polyol pathway. Multiple
factors  are  likely  to  be  involved  in  predisposing  diabetic
subjects to DR, as evidenced by the fact that many, but not all,
diabetic  patients  develop  one  or  more  microvascular
complications. It has been reported that the prevalence of DR
is associated with increased erythrocyte ALR2 protein levels
[25].  This  observation  is  based  on  previous  studies  that
revealed that erythrocyte ALR2 protein levels correlates with
ALR2 protein levels in retinal cells, particularly pericytes
[25,26].  However,  it  was  shown  that  ALR2  in  human
erythrocytes exists in activated and unactivated forms, and in
hyperglycemia the total activity of ALR2 increases [15,27].
Hence, correlating total ALR2 activity with DR prevalence
may provide an important link between an easily measurable
marker in peripheral blood and risk of progression toward eye
disease. In this study, we examined the activity of ALR2 in
erythrocytes obtained from diabetic patients with and without
retinopathy. Further, we also measured the levels of sorbitol
as a surrogate marker for ALR2 activity levels in erythrocytes.
These data demonstrate that erythrocyte ALR2 activity and
sorbitol levels are significantly elevated in diabetic patients
with  retinopathy  as  compared  with  diabetics  without
retinopathy or patients without diabetes.
METHODS
Subjects and study design: A hospital-based prospective case
control  study  was  conducted.  The  study  protocols  were
approved  by  the  Institutional  Ethics  Committees  of  the
institutes involved. Subjects were recruited from the patients
who visited the Sarojini Devi Eye Hospitals and Institute of
Ophthalmology,  Hyderabad,  India  and  Department  of
Endocrinology, Osmania General Hospital, Hyderabad, India.
A total of 362 T2D subjects (198 with DR, 164 without ocular
complications)  and  66  normal  subjects  were  investigated.
Written consent was obtained from the participants after they
were given an explanation of the study details. A complete
history of each participant, with respect to age, gender, clinical
symptoms,  diabetes  type  and  duration,  medication,  and
socioeconomic  background,  was  collected  using  a  well
designed questionnaire. None of the diabetics in this study
were on insulin treatment. The fundus of each subject was
evaluated by both direct and indirect ophthalmoscopy, and DR
was  defined  and  classified  according  to  Viswanath  and
McGavin [28]. The presence of retinal microaneurysm, dot
and  slot  hemorrhages,  intraretinal  microvascular
abnormalities,  and  cotton  wool  spots  were  defined  as
nonproliferative DR (NPDR), which was then categorized as
mild, moderate, severe, and diabetic maculopathy. Formation
of new vessels with and without bleeding and production of
vitreous hemorrhage was defined as proliferative DR (PDR).
Sample collection and processing: Blood was drawn from the
subjects into anticoagulant tubes and immediately transported
to the laboratory on ice. Red blood cells (RBC) were separated
by centrifugation, washed thrice with saline, and stored at –
85 °C until further analysis.
Glucose estimation: Glucose was estimated in plasma by the
GOD-POD  method  using  a  kit  (BioSystems,  Barcelona,
Spain). Ten µl of serum or standard (100 mg/dl glucose) was
added to reagent A (100 mM phosphate buffer, pH 7.5 with 5
mM phenol, 10 U/ml glucose oxidase, 1 U/ml peroxidase, and
0.4 mM 4-aminoantipyrine) and incubated for 5 min at 37 oC.
Absorbance was measured at 505 nm in a spectrophotometer.
Glycosylated  hemoglobin:  HbA1C  was  estimated  by  ion-
exchange chromatography using a kit (BioSystems). Fifty µl
of blood was added to reagent 1 (50 mM potassium phosphate,
pH 5.0 with 5 g/l detergent and 0.95g/l sodium azide) and
mixed thoroughly to prepare the hemolysate. From this 50 µl
of  hemolysate  was  added  to  the  ion-exchange  resin  and
washed with 2.2 ml of reagent 2 (30 mM potassium phosphate,
pH 6.5 containing 0.95 g/l sodium azide). HbA1C was eluted
using  reagent  3  (72  mM  potassium  phosphate,  pH  6.5
containing 0.95 g/l sodium azide). Absorbance of the eluted
HbA1C was read at 415 nm in a spectrophotometer.
Aldose reductase activity: A 10% erythrocyte suspension was
made by adding 50 mM sodium phosphate buffer, pH 7.4,
containing  150  mM  NaCl.  The  suspension  was  lysed  by
repeated freezing and thawing (three cycles) and centrifuged
to  remove  insoluble  material,  if  any.  ALR2  activity  was
measured  spectrophotometrically  using  an  appropriately
diluted  hemolysate  according  to  a  previously  described
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594method  [29]  using  a  SpectraMax  spectrophotometer
(Molecular Devices, Sunnyvale, CA). One unit was defined
as  micromoles  NADPH  oxidized/g  Hb/  min.  The  assay
mixture  in  1  ml  contained  50  µmol  potassium  phosphate
buffer pH 6.2, 0.4 mmol lithium sulfate, 5 µmol 2-mercapto
ethanol, 10 µmol DL-glyceraldehyde, 0.1 µmol NADPH and
enzyme  preparation  (hemolysate).  The  assay  mixture  was
incubated at 37 oC and initiated by the addition of NADPH at
37 oC. The change in the absorbance at 340 nm due to NADPH
oxidation was followed.
Estimation  of  sorbitol:  Sorbitol  was  extracted  by
homogenizing RBC in nine volumes of 0.8 M perchloric acid.
The homogenate was centrifuged at 5,000g at 4 °C for 10 min,
and the pH of the supernatant was adjusted to 3.5 with 0.5 M
potassium carbonate. The sorbitol content of the supernatant
was  measured  by  fluorometric  method  as  described
previously [30] using a fluorometer (Jasco-FP-6500, Tokyo,
Japan). One ml reaction mixture, consisted of 50 µmol glycine
buffer,  pH  9.4,  2  µmol  magnesium  chloride,  0.2  µmol
nicotinamide adenine dinucleotide (NAD) and protein-free
supernatant, was incubated for 5 min at 37 oC and reaction was
initiated by the addition of 0.6 U of sorbitol dehydrogenase.
The  relative  fluorescence  due  to  NADH  formation  was
measured in a fluorometer with an excitation wavelength at
360 nm and an emission wavelength of 452 nm. Sorbitol
standards, ranging from 0.2-9.0 µg/ml, were analyzed by the
same to generate a standard curve.
Statistical  analysis:  The  data  were  expressed  as  mean  ±
standard deviation. Mean values were compared by one-way
ANOVA with post hoc tests of least significant difference
method.  Differences  between  comparison  groups  were
considered to be significant where p<0.05. Correlations were
calculated to study relationship of ALR2 and sorbitol with
other variables. P values were also calculated for ALR2 in
these groups.
RESULTS
Data on mean age, duration of diabetes, levels of glucose,
glycosylated hemoglobin, ALR2 activity, and sorbitol with
respect  to  gender  distribution  for  nondiabetic  control,
diabetics  without  retinopathy  (DNR)  and  diabetics  with
retinopathy (DR) groups are summarized in Table 1. There
was  no  significant  difference  (p>0.05)  between  male  and
female  subjects  in  all  three  groups  with  respect  to  the
TABLE 1. CLINICAL AND BIOCHEMICAL FEATURES OF THE STUDY SUBJECTS
Group/
parameter
Nondiabetic Diabetes without retinopathy Diabetic retinopathy
Male Female Male Female Male Female
Age (Years)
Mean
n
S.D.
54.37
43
12.925
56.00
23
12.803
50.91
64
11.394
49.09
100
9.242
53.09
122
10.188
54.49
76
7.431
Glucose (mg/dL)
Mean
n
S.D.
110.50
43
25.060
104.22
23
17.9
210.92
64
111.06
217.91
100
101.50
244.15
115
97.70
251.22
76
106.73
Duration (Years)
Mean
n
S.D.
0.00
43
0.000
0.00
23
0.000
5.26
64
4.200
6.79
100
4.850
9.43
115
6.073
11.04
76
6.673
HbA1C (%)
Mean
n
S.D.
5.20
20
1.77
5.11
13
1.27
7.90
14
1.95
7.48
26
2.26
8.40
42
2.64
8.24
24
1.68
ALR2 (units/g Hb)
Mean
n
S.D.
2.49
43
1.60
3.6
23
2.3
3.60
64
2.23
3.5
100
2.36
4.62
122
3.05
4.67
76
2.69
Sorbitol (μg/mL)
Mean
n
S.D.
2.9
14
0.99
3.0
10
1.4
3.4
10
1.4
3.8
27
1.0
4.5
26
1.7
5.3
17
2.3
The distribution of age, random glucose, duration of diabetes, glycosylated hemoglobin (HbA1C), ALR2 activity and sorbitol
levels between male and females in nondiabetic control, diabetes without retinopathy (DNR) and diabetes with retinopathy (DR)
groups. The data (mean ± standard deviation (SD)) indicate no significant difference between the genders. (n = number).
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595measured parameters. Therefore, the pooled data for men and
women in respective groups were considered for subsequent
analysis.
As can be seen from Figure 1, erythrocyte ALR2 activity
in  the  DNR  group  was  not  significantly  different  from
nondiabetic control (p>0.05). Interestingly, ALR2 activity in
the DR group was significantly different not only from the
control group but also from the DNR group (p<0.05) (Figure
1). However, the ALR2 activity ranged from 0.2 units/g Hb
in the control group to 18.6 units/g Hb in the DR group with
considerable  overlap  between  the  groups.  Therefore,  we
examined the data after distribution of individuals into one of
Figure 1. Erythrocyte aldose reductase
activity. Data represent mean ± standard
deviation of aldose reducatase (ALR2)
activity in nondiabetic control (n=66)
and  diabetics  without  diabetic
retinopathy  (DNR;  n=164)  and  those
with diabetic retinopathy (DR; n=182).
Asterisk  (*)  designates  statistical
significance (p<0.05) in comparison to
the other groups.
Figure  2.  Percentage  distribution  of
aldose reductase activity levels. Aldose
reductase (ALR2) activity is distributed
into <3, 3–6, 6–9, and >9 units/g Hb
subgroups in nondiabetic control, and
diabetics  without  diabetic  retinopathy
(DNR),  and  diabetics  with  diabetic
retinopathy  (DR).  Percentage
distribution of ARL2 activity with <3
units is significantly (p<0.05) different
between  the  groups.  Percentage
distribution of ARL2 activity with >9
units is significantly (p<0.05) different
between DNR and DR groups.
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596four subgroups defined according to level of ALR2 activity
(Figure  2).  Percentage  distributions  of  ALR2  activity
indicated that most subjects in the control group had <3.0 units
(58%), about 33% had 3–6 units, and only 9% had activity in
the category of 6–9 units. Approximately 43% of the subjects
in DNR group had <3.0 units, 35% had 3–6 units, and about
18% had ALR2 activity in the category 6–9 units. Whereas
most of the DR subjects (46%) had 3–6 units of ALR2 activity,
a substantial proportion (20%) had 6–9 units activity, and
those  with  >9.0  units  of  ALR2  activity  were  found
predominantly in this group (6%). These results suggest that
prevalence of DR is associated with higher ALR2 activity.
However, there was no significant difference in ALR2 activity
between NPDR and PDR (4.36 units; n=114 vs 4.78; n=84).
We further measured the levels of sorbitol, the product of
ALR2-mediated reduction of glucose, in a subset of subjects
in all three groups. While the levels of sorbitol were found to
be higher in the DNR group as compared to control group, the
difference was not statistically significant (p>0.05). However,
sorbitol levels were significantly (p<0.05) higher in the DR
group as compared to both the DNR and the control groups
(Figure 3). Increased levels of sorbitol in DR patients were
consistent  with  the  higher  ALR2  activity  in  DR  patients.
Activity  of  ALR2  was  not  correlated  with  age,  glucose,
diabetes  duration,  and  HbA1C  levels  in  all  three  groups
(control, DNR, and DR; see Table 2) as well as with pooled
data. Similarly, levels of sorbitol did not correlate with age,
glucose, diabetes duration, and HbA1C levels in all three
groups (Table 3) as well as with pooled data. However, as
Figure 4 demonstrates, ALR2 activity was correlated with
sorbitol levels (r=0.188; p<0.05) . As with ALR2 activity,
there was no significant difference in sorbitol levels between
NPDR and PDR subjects (4.80 mg/mL; n=41 vs 5.02; n=27).
DISCUSSION
Although uncontrolled hyperglycemia is the major factor, the
link between diabetes and susceptibility to various secondary
complications has not been unraveled. The polyol pathway of
glucose metabolism is activated when intracellular glucose
levels are high [31]. The activation is immediately linked to
hyperglycemia and occurs prominently in tissues that develop
complications [31,32]. In addition, polymorphisms associated
with regions flanking the ALR2 gene have been implicated in
human susceptibility to DR and other diabetic complications
[21,22]. There is also a strong evidence to show that diabetic
complications including DR are associated with increased
oxidative stress [5], and activation of polyol pathway is known
to  contribute  to  oxidative  stress  [33].  Evidence  for  the
involvement  of  ALR2  in  DR  comes  from  studies  that
demonstrated ALR2 was present in different cell types of
TABLE 2. CORRELATION OF ALDOSE REDUCTASE ACTIVITY WITH OTHER CLINICAL VARIABLES
Variables Correlation coefficient values
Nondiabetic Diabetes without
retinopathy
Diabetic retinopathy
Age −0.181 −0.015 0.047
Glucose 0.030 −0.021 0.001
Duration — −0.049 0.016
HbA1C 0.092 −0.177 0.051
Correlation of aldose reductase (ALR2) activity with age,
glucose,  diabetes  duration,  and  glycosylated  hemoglobin
(HbA1C) in different groups indicate all these correlates are
not significant with ALR2 activity at p>0.05.
Figure  3.  Erythrocyte  sorbitol  levels.
Data  represent  mean  ±  standard
deviation in nondiabetic control (n=31)
and  diabetics  without  diabetic
retinopathy (DNR; n=44) and those with
diabetic  retinopathy  (DR;  n=52).
Asterisk  (*)  designates  statistical
significance (p<0.05) in comparison to
the other groups.
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597retina [17-20]. In addition, disruption of the ALR2 gene leads
to a reduction in lesions associated with DR in a diabetic
mouse model [34]. However, studies with ARI have yielded
inconsistent results against DR or diabetic-like retinopathy in
experimental animals [14,35] and in clinical trials to assess
efficacy  against  various  diabetic  complications  [36].
Nevertheless, ALR2 remains an intriguing candidate/target
for the treatment of secondary complications. Hence, the role
of the polyol pathway vis á vis ALR2 in the pathogenesis of
diabetic  complications,  particularly  DR,  requires  further
investigations from various angles.
The present study investigated the functional state of
erythrocyte ALR2 in DR patients in comparison with DNR.
The  results  demonstrated  that  the  activity  of  ALR2  is
significantly  higher  in  DR  patients  as  compared  to  DNR
patients. Earlier studies had focused on enzyme activity and
protein levels of ALR2 in diabetic complications in humans
[reviewed in 22]. In type 1 diabetes, patients with the highest
ALR2 activity were found to be four times more likely to
develop  diabetic  microvascular  complications  than  those
whose activity was similar to normal. Oishi et al. suggested
that increased prevalence of DR is correlated with increased
erythrocyte AR protein levels, particularly the prevalence of
DR in patients who have diabetes for fewer than 10 years
[25]. A correlation between erythrocyte ALR2 protein levels
and  diabetic  cataract,  particularly  posterior  subcapsular
cataract,  has  also  been  reported  [37].  However,  in  these
studies ALR2 levels were determined by ELISA and not by
catalytic activity. The underlying assumption behind these
studies was that erythrocyte ALR2 might reflect ALR2 in
pericytes  and  lens,  the  vulnerable  cell  types  in  DR  and
cataract, respectively. The best way to assess the functional
role of ALR2 in DR is to determine ALR2 in retinal pericytes
and  capillaries.  However,  a  noninvasive  procedure  is  not
currently available to make such measurements. Therefore,
we and others used erythrocytes as a surrogate tissue for
enzyme measurements.
Increased  oxidative  stress  has  been  linked  to  the
development of diabetic complications [5] and altered redox
homeostasis is known to affect ALR2 activity. For example,
oxidation  of  cysteine  residue  under  oxidative  conditions
modulates ALR2 activity [38]. Thus the specific activity of
the protein may also be critical for the development of diabetic
complications. The results of the present study show that
higher activity of ALR2 is associated with prevalence of DR.
On the other hand, we found no significant difference in ALR2
activity between NPDR and PDR, indicating higher ALR2
might be involved in the initiation of disease, but not in the
progression,  which  needs  further  investigation.  However,
there was a large variation in ALR2 activity, and there was
considerable overlap of activity between nondiabetic control,
DNR, and DR groups. Nevertheless, percentage distributions
of ALR2 activity indicate that a substantial number of subjects
in the DR group had activity in the category of 6–9 units, and,
most important, >9.0 units of ALR2 activity was found almost
exclusively in this group.
Development  of  DR  and  other  microvascular
complications are generally linked to diabetes duration and
Figure  4.  Correlation  between
erythrocyte  sorbitol  levels  and  aldose
reductase  activity.  Correlation
(r=0.188) between erythrocyte sorbitol
levels  and  aldose  reductase  (ALR2)
activity  in  control,  diabetics  without
diabetic  retinopathy  (DNR),  and
diabetics  with  retinopathy  (DR)  was
found  to  be  significant  at  p<0.05.
Correlation was done for those samples
in which sorbitol was determined.
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598patient age [25,39-41]. It is estimated that DR develops in
more than 75% of diabetics who have had diabetes for 15–20
years. Interestingly, the higher ALR2 activity in the DR group
in the present study was not associated with diabetes duration
and patient age. This observation suggests that ALR2 activity
might serve as an independent risk identification factor for
DR, irrespective of duration of diabetes and age of the patient.
In this study, we found a substantial number of DR patients
whose duration of diabetes was less than 15 years: Of 198 DR
patients in our study, 28% had been diabetic for <5 years, 35%
for  <10  years,  and  35%  for  >15  years.  This  may  have
implications in the development of DR in Indian context. Even
though  the  prevalence  of  microvascular  complications  of
diabetes-like retinopathy is comparatively lower in the Indian
populations, the age of onset of diabetes in this part of the
world  is  much  earlier  [2,42].  The  impact  of  early  onset
diabetes  and  development  of  complications  with  shorter
duration of diabetes needs to be addressed. We also note that,
in  contrast  to  studies  [41,43,44],  we  did  not  observe  an
association between HbA1C and prevalence of DR in our
study population. Furthermore, the increase in ALR2 activity
in  DR  group  was  not  associated  with  HbA1C  levels.  A
previous study also reported that while the protein level of
ALR2 in erythrocyte was associated with DR, there was no
correlation  between  enzyme  levels  and  age,  duration  of
diabetes, fasting blood glucose, and HbA1C in patients with
T2D [45]. The interindividual variability of ALR2 protein
content has been shown to be associated with variation in
polyol pathway metabolites [46], which could be associated,
at least in part, to the prevalence of diabetic complications. A
significant proportion (30%) of DR patients in our study were
shown to have >6 units of ALR2 activity, whereas most of the
DNR  patients  and  nondiabetics  had  <6.0  units  activity.
Although relatively few of our study participants had ALR2
activity above 9.0 units, the strong association of these high
enzyme  levels  with  the  DR  group  suggests  that  elevated
erythrocyte ALR2 activity may represent a significant risk
factor for the susceptibility of diabetic subjects to develop DR.
Further, the possibility that patients in DNR group with 6–9
units  activity  might  eventually  develop  DR  needs  further
investigation.
TABLE 3. CORRELATION OF SORBITOL LEVELS WITH OTHER CLINICAL VARIABLES
Variables Correlation coefficient values
Nondiabetic Diabetes without
retinopathy
Diabetic retinopathy
Age 0.067 −0.033 −0.146
Glucose 0.087 0.012 −0.047
Duration — −0.208 −0.015
HbA1C 0.047 0.297 0.130
Correlation  of  sorbitol  levels  with  age,  glucose,  diabetes
duration, and glycosylated hemoglobin (HbA1C) in different
groups indicate that all these correlates are not significant with
sorbitol levels at p>0.05.
Measurement  of  ALR2  activity  by  the
spectrophotometric method using DL-glyceraldehyde as the
aldehyde substrate could lead to confusing results because
other aldo-keto reductases are active with this substrate [47].
Thus, we measured sorbitol level in a subset of samples as an
index of ALR2 activity since ALR2 is unique among human
aldo-kedo reductases in its ability to catalyze the NADPH-
dependent conversion of glucose to sorbitol [48]. As with
ALR2 activity, the sorbitol levels were significantly higher in
the DR group as compared to the control and DNR groups
(Figure 3). It should be noted that there was linear correlation
between sorbitol levels and ALR2 activity irrespective of the
group  to  which  they  belonged  (Figure  4).  Moreover,  the
contribution of other aldo-keto reductases to the apparent
ALR2 activity is likely to be minimal because of the good
correlation  between  apparent  ALR2  activity  levels  and
sorbitol levels in RBC. In addition, sorbitol levels were not
associated with diabetes duration, age, glucose, and HbA1c
levels of the subjects. As with ALR2 activity, we observed
that sorbitol levels were also not related to the severity of DR,
as there was no significant difference between NPDR and
PDR subjects.
Based on the results of the current study, it is reasonable
to hypothesize that some diabetics with ALR2 activity levels
above a certain “threshold” level might be predisposed to
develop  DR.  However,  validation  of  this  hypothesis  will
require additional longitudinal studies. Additional studies are
needed  to  determine  whether  ALR2  activity  and  sorbitol
levels in erythrocytes may have value as quantitative traits that
need to be considered, along with other known risk factors
(including  genetic  susceptibility),  to  assess  risk  for
development of DR.
Although the beneficial impact of strict glycemic control
on  prevention  of  diabetic  complications  has  been  well
established,  most  individuals  with  diabetes  rarely  achieve
consistent euglycemia. Hence, agents that can substantially
delay  or  prevent  the  onset  and  development  of  diabetic
complications, irrespective of glycemic control, would offer
many advantages. In principle, ARI can be included in this
category.  Although  clinical  trials  of  ARI  have  failed  to
demonstrate efficacy against various diabetic complications,
trials of other compounds such a protein kinase Cβ inhibitor
have also failed to show efficacy against progression of DR
[49]. Thus, intensive research continues to identify and test
both synthetic as well as natural products for their therapeutic
value to prevent the onset as well as progression of diabetic
complications [29,50-52].
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